Dr. Roxana Moslehi, associate professor of epidemiology at the University at Albany School of Public Health and Genetic Epidemiologist at the Cancer Research Center, has been awarded a $426,477 R21 grant from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), to conduct a study entitled “Chronic Fatigue Syndrome, Immune Dysregulation and Non-Hodgkin’s Lymphoma: A Genetic Epidemiologic Investigation”. The purpose of the study is to determine the role of genetic predisposition and immune dysregulation in the etiology of chronic fatigue syndrome (CFS) and to explore the possible link between CFS and the risk of cancer, specifically non-Hodgkin’s lymphoma (NHL).
The etiology of CFS, a disabling disorder affecting more than one million people in the United States (U.S.), is unknown. CFS appears to be a heterogeneous disorder with a variety of clinical presentations and postulated mechanism. Dr. Moslehi, the principal investigator of this R21 grant, and her colleagues at the collaborating Universities and Medical Centers have designed a molecular epidemiologic investigation to explore the role of genetic predisposition and specific immune factors in the etiology of CFS using a well-defined cohort of patients and appropriately-matched relative and nonrelative controls.
This R21 project has the potential to provide mechanistic insight with respect to the role of genetic and immunologic factors in the etiology of CFS, provide clues as to whether CFS is an autoimmune disorder, and provide additional plausibility for the link between CFS and malignancy, specifically NHL.